Providence hospitals part of anti-viral drug study
Providence Health said Monday, March 30, that two Portland-area hospitals will take part in a national clinical trial of an anti-viral drug that could be used to fight the COVID-19 virus.
Hospital officials said some COVID-19 positive patients at Providence St. Vincent and Providence Portland medical centers could take part in a phase-three clinical trial of Remdesavir. The intravenous drug produced by biopharmaceutical company Gilead Sciences Inc. of Foster City, California, was used in the global fight against the Ebola outbreak.
Gilead Sciences is in two phase-three clinical studies to evaluate remdesivir in adults diagnosed with COVID-19. The U.S. Food and Drug Administration put the drug in rapid review. The study will use about 1,000 patients across the country. It should be completed by May.
You count on us to stay informed and we depend on you to fund our efforts. Quality local journalism takes time and money. Please support us to protect the future of community journalism.
